tau 和淀粉样蛋白正电子发射断层扫描成像预测有和无临床前阿尔茨海默病的老年人的驾驶表现。
Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.
机构信息
Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
出版信息
J Alzheimers Dis. 2018;61(2):509-513. doi: 10.3233/JAD-170521.
Abstract
Abnormal levels of Alzheimer's disease (AD) biomarkers, measured by positron emission tomography imaging using amyloid-based radiotracers and cerebrospinal fluid, are associated with impaired driving performance in older adults. We examined whether preclinical AD staging, defined using amyloid imaging and tau imaging using the radiotracer T807 (AKA flortaucipir or AV-1451), was associated with receiving a marginal/fail rating on a standardized road test (n = 42). Participants at Stage 2 (positive amyloid and tau scans) of preclinical AD were more likely to receive a marginal/fail rating compared to participants at Stage 0 or 1. Stage 2 preclinical AD may manifest in worse driving performance.
摘要
阿尔茨海默病（AD）生物标志物水平异常，可通过正电子发射断层扫描成像（使用基于淀粉样蛋白的放射性示踪剂和脑脊液测量）进行评估，与老年人驾驶表现受损有关。我们研究了使用淀粉样蛋白成像和tau 成像（使用放射性示踪剂 T807，又称 flortaucipir 或 AV-1451）定义的临床前 AD 分期是否与标准化道路测试中的边缘/失败评分相关（n=42）。与临床前 AD 0 期或 1 期相比，临床前 AD 2 期（阳性淀粉样蛋白和 tau 扫描）患者更有可能获得边缘/失败评分。临床前 AD 2 期可能表现为驾驶表现更差。
相似文献
1
Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.tau 和淀粉样蛋白正电子发射断层扫描成像预测有和无临床前阿尔茨海默病的老年人的驾驶表现。
J Alzheimers Dis. 2018;61(2):509-513. doi: 10.3233/JAD-170521.
2
Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.抑郁和阿尔茨海默病生物标志物可预测驾驶能力下降。
J Alzheimers Dis. 2018;66(3):1213-1221. doi: 10.3233/JAD-180564.
3
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.Tau 正电子发射断层扫描作为临床前和前驱期阿尔茨海默病预后标志物的准确性：与淀粉样蛋白正电子发射断层扫描和磁共振成像的头对头比较。
JAMA Neurol. 2021 Aug 1;78(8):961-971. doi: 10.1001/jamaneurol.2021.1858.
4
The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.阿尔茨海默病病理学的脑脊液标志物与正电子发射断层扫描tau成像之间的关系。
Brain. 2016 Aug;139(Pt 8):2249-60. doi: 10.1093/brain/aww139. Epub 2016 Jun 10.
5
Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.候选 tau PET 配体 18F-AV-1451 的区域特征再现了 Braak 组织病理学分期的关键特征。
Brain. 2016 May;139(Pt 5):1539-50. doi: 10.1093/brain/aww023. Epub 2016 Mar 2.
6
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.氟替卡匹尔PET tau蛋白结合与淀粉样蛋白负荷、临床诊断、年龄和认知之间的关系。
Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.
7
18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.18F-Flortaucipir PET 与阿尔茨海默病导致的轻度认知障碍患者的脑脊液、认知和神经影像学的相关性。
J Alzheimers Dis. 2020;74(2):589-601. doi: 10.3233/JAD-191330.
8
Identifying Preclinical Alzheimer's Disease Using Everyday Driving Behavior: Proof of Concept.利用日常驾驶行为识别临床前阿尔茨海默病：概念验证。
J Alzheimers Dis. 2021;79(3):1009-1014. doi: 10.3233/JAD-201294.
9
A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer's Disease.临床前阿尔茨海默病自然驾驶的 2.5 年纵向评估。
J Alzheimers Dis. 2019;68(4):1625-1633. doi: 10.3233/JAD-181242.
10
Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.使用脑脊液磷酸化tau 和 AV1451 正电子发射断层扫描技术对阿尔茨海默病生物标志物差异进行特征分析。
JAMA Neurol. 2020 Apr 1;77(4):508-516. doi: 10.1001/jamaneurol.2019.4749.
引用本文的文献
1
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.一篇关于用于tau神经原纤维缠结正电子发射断层扫描成像的氟替卡匹文献综述。
Brain Commun. 2023 Nov 16;6(1):fcad305. doi: 10.1093/braincomms/fcad305. eCollection 2024.
2
Driving Automation for Older Adults with Preclinical Alzheimer's Disease.针对有临床前阿尔茨海默病的老年人的驾驶自动化。
Gerontology. 2023;69(11):1307-1314. doi: 10.1159/000531263. Epub 2023 Aug 9.
3
Everyday Driving and Plasma Biomarkers in Alzheimer's Disease: Leveraging Artificial Intelligence to Expand Our Diagnostic Toolkit.阿尔茨海默病患者的日常驾驶行为与血浆生物标志物：利用人工智能拓展我们的诊断工具包。
J Alzheimers Dis. 2023;92(4):1487-1497. doi: 10.3233/JAD-221268.
4
Driving assessment in preclinical Alzheimer's disease: progress to date and the path forward.临床前阿尔茨海默病的驾驶能力评估：目前的进展和未来的道路。
Alzheimers Res Ther. 2022 Nov 8;14(1):168. doi: 10.1186/s13195-022-01109-1.
5
Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimer's Disease: The Role of Naturalistic Driving Studies.增进我们对临床前和早期有症状阿尔茨海默病驾驶变化的理解：自然驾驶研究的作用。
J Alzheimers Dis Rep. 2022 Aug 11;6(1):521-528. doi: 10.3233/ADR-220024. eCollection 2022.
6
Verbal Learning as a predictor of risks of accidents in elderly drivers.言语学习作为预测老年驾驶员事故风险的指标。
Arq Neuropsiquiatr. 2022 Jan;80(1):30-36. doi: 10.1590/0004-282X-ANP-2021-0054.
7
Using Naturalistic Driving Data to Predict Mild Cognitive Impairment and Dementia: Preliminary Findings from the Longitudinal Research on Aging Drivers (LongROAD) Study.利用自然驾驶数据预测轻度认知障碍和痴呆症：老年驾驶员纵向研究（LongROAD）的初步结果
Geriatrics (Basel). 2021 Apr 23;6(2):45. doi: 10.3390/geriatrics6020045.
8
Driving Ability in Alzheimer Disease Spectrum: Neural Basis, Assessment, and Potential Use of Optic Flow Event-Related Potentials.阿尔茨海默病谱系中的驾驶能力：神经基础、评估以及视流事件相关电位的潜在应用
Front Neurol. 2018 Sep 7;9:750. doi: 10.3389/fneur.2018.00750. eCollection 2018.
9
Using the A/T/N Framework to Examine Driving in Preclinical AD.使用A/T/N框架研究临床前阿尔茨海默病中的驾驶情况。
Geriatrics (Basel). 2018 Jun;3(2). doi: 10.3390/geriatrics3020023. Epub 2018 May 2.
本文引用的文献
1
Preclinical Alzheimer's disease and longitudinal driving decline.临床前阿尔茨海默病与纵向驾驶能力下降
Alzheimers Dement (N Y). 2017 Jan;3(1):74-82. doi: 10.1016/j.trci.2016.11.006.
2
A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study.一项针对老年人和临床前阿尔茨海默病驾驶行为的自然主义研究：一项初步研究。
J Appl Gerontol. 2019 Feb;38(2):277-289. doi: 10.1177/0733464817690679. Epub 2017 Jan 29.
3
Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk.临床前阿尔茨海默病中的脑淀粉样蛋白与驾驶风险增加有关。
Alzheimers Dement (Amst). 2016 Nov 29;6:136-142. doi: 10.1016/j.dadm.2016.10.008. eCollection 2017.
4
Tau PET imaging: present and future directions.tau蛋白正电子发射断层显像：现状与未来发展方向
Mol Neurodegener. 2017 Feb 20;12(1):19. doi: 10.1186/s13024-017-0162-3.
5
Creating a driving profile for older adults using GPS devices and naturalistic driving methodology.使用全球定位系统设备和自然驾驶方法为老年人创建驾驶档案。
F1000Res. 2016 Sep 26;5:2376. doi: 10.12688/f1000research.9608.2. eCollection 2016.
6
Development and interval testing of a naturalistic driving methodology to evaluate driving behavior in clinical research.一种用于评估临床研究中驾驶行为的自然驾驶方法的开发与间隔测试。
F1000Res. 2016 Jul 15;5:1716. doi: 10.12688/f1000research.9150.2. eCollection 2016.
7
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.评估 Tau 成像在阿尔茨海默病分期中的作用及揭示β-淀粉样蛋白与 Tau 病之间的相互作用。
JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.
8
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.阿尔茨海默病谱系中 tau 和淀粉样蛋白的体内皮质扩散模式。
Ann Neurol. 2016 Aug;80(2):247-58. doi: 10.1002/ana.24711. Epub 2016 Jul 8.
9
The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.阿尔茨海默病病理学的脑脊液标志物与正电子发射断层扫描tau成像之间的关系。
Brain. 2016 Aug;139(Pt 8):2249-60. doi: 10.1093/brain/aww139. Epub 2016 Jun 10.
10
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.阿尔茨海默病中的tau蛋白和淀粉样β蛋白成像、脑脊液检测及认知情况
Sci Transl Med. 2016 May 11;8(338):338ra66. doi: 10.1126/scitranslmed.aaf2362.
Zotero 插件